Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25702356 | 0.82 | NOS3 (0.35) | NOS3NOS2MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL23588699 | 0.79 | NOS3 (0.33) | NOS3NOS2MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL24322401 | 0.79 | NOS2 (0.44) | NOS3NOS2 | |
| SCHEMBL16646966 | 0.78 | MAPK1 (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL26577996 | 0.77 | ADRA2A (0.35) | NOS3NOS2MAPK1 | |
| SCHEMBL22924111 | 0.76 | MAPK1 (0.36) | NOS3NOS2MAPK1 | |
| SCHEMBL23023256 | 0.75 | GSK3B (0.33) | MAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL25702607 | 0.74 | TLR8 (0.31) | NOS3NOS2 | |
| SCHEMBL19115954 | 0.73 | JAK2 (0.41) | NOS3NOS2MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL19115889 | 0.73 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021219072-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC | 2021-01-28 | — | — | US | disclosed |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | ARAXES PHARMA LLC (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024501-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | NOS3 3714/4885NOS2 3457/4885MAPK1 146/4885 |
| US-10736897-B2 | Compounds and methods of use thereof for treatment of cancer | KRAS, NRAS, HRAS | NOS3 4556/4885NOS2 4542/4885MAPK1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.